Provided by Tiger Trade Technology Pte. Ltd.

CG Oncology Inc.

64.62
-2.0500-3.07%
Post-market: 64.850.2300+0.36%19:36 EDT
Volume:889.25K
Turnover:57.68M
Market Cap:5.46B
PE:-31.03
High:67.63
Open:67.13
Low:64.15
Close:66.67
52wk High:69.35
52wk Low:14.80
Shares:84.44M
Float Shares:67.76M
Volume Ratio:0.58
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0826
EPS(LYR):-2.0826
ROE:-21.67%
ROA:-15.42%
PB:7.25
PE(LYR):-31.03

Loading ...

RBC Raises Price Target on CG Oncology to $73 From $61, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 21

CG Oncology price target raised to $73 from $61 at RBC Capital

TIPRANKS
·
Jan 21

CG Oncology Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 17

CG Oncology price target raised to $70 from $55 at Piper Sandler

TIPRANKS
·
Jan 16

CG Oncology Expands At-The-Market Equity Offering Capacity

TIPRANKS
·
Jan 14

CG Oncology Inc Files for Offering of up to $550 Mln Common Stock - SEC Filing

THOMSON REUTERS
·
Jan 14

CG Oncology Director James Mulay Reports Disposal of Common Shares

Reuters
·
Jan 14

CG Oncology Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 13

Wedbush Raises Price Target on CG Oncology to $77 From $70, Keeps Outperform Rating

MT Newswires Live
·
Jan 12

Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum

Simply Wall St.
·
Jan 11

Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology

TIPRANKS
·
Jan 10

CG Oncology price target raised to $66 from $62 at Truist

TIPRANKS
·
Jan 10

CG Oncology price target raised to $93 from $89 at Morgan Stanley

TIPRANKS
·
Jan 10

CG Oncology Up Over 27%, on Track for Record High Close and Record Percent Increase -- Data Talk

Dow Jones
·
Jan 10

Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January

Benzinga
·
Jan 10

CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday

Benzinga_recent_news
·
Jan 10

CG Oncology: Early PIVOT-006 Readout, Strengthened Creto Outlook, and 2026 Catalyst Wave Support Buy Rating and Higher $85 Target

TIPRANKS
·
Jan 10

CG Oncology rises 16.0%

TIPRANKS
·
Jan 09

CG Oncology Accelerates Phase 3 Bladder Cancer Trial Timeline

TIPRANKS
·
Jan 09

BRIEF-Cg Oncology Provides Updated Timeline For Pivot-006 Phase 3 Topline Data In Intermediate-Risk Nmibc

Reuters
·
Jan 09